The Global Initiative for Asthma (GINA) recommends the concurrent use of self-report and pharmacy refill data to assess treatment adherence. However, clinical evidence to support this combined approach is limited.
INTRODUCTION
Up to 60% of patients do not fully adhere to their prescribed treatment regimen [1] [2] [3] .
Suboptimal adherence leads to worse clinical outcomes, more exacerbations, and higher morbidity and mortality rates [4] [5] [6] [7] [8] . A wide range of factors can negatively impact adherence to prescription medications [9, 10] , including demographic variables, disease-related factors, side-effects, comorbidities, and life-style factors, among others. Inhaler-specific factors that can influence adherence include improper inhaling technique, difficulties associated with the use of multiple devices, complex treatment regimens, and prolonged treatment duration [10] [11] [12] .
Numerous methods, both objective and subjective, are available to assess treatment adherence in patients with asthma and chronic obstructive pulmonary disease (COPD) [13] . Although the most reliable methods are objective measures such as electronic monitoring devices and blood tests, the use of these instruments in routine clinical practice is impractical. By contrast, validated self-report questionnaires, such as the Test of Adherence to Inhalers (TAI)[12, 14, 15] , offer clinicians a straightforward, inexpensive approach to assessing adherence, with acceptable reliability. In many regions, objective refill data can be obtained electronically from pharmacy dispensing records. Due to the simplicity, low cost, and acceptable reliability of these methods, the Global Initiative for Asthma (GINA) and other recent guidelines recommend using both methods concurrently to assess treatment adherence [16] [17] . However, clinical Prescription refill data were obtained from the patients' pharmacy records to determine the number of inhaler devices prescribed by the physician and dispensed by the pharmacy in the last six months. In accordance with standard practice [24] , the refill threshold for good adherence was set at ≥ 80%, which assumes that the patient picked up his/her monthly prescription at least 5 times during the six-month study period. Thus, any patient with a pharmacy refill rate (PRR) < 80% was considered nonadherent. In all cases, adherence was based on the primary inhaler, which was determined by the treating physician. If the prescription involved a combination of drugs in a single inhaler, then this device was considered the primary inhaler. In all other cases, the primary inhaler was the device designed to deliver inhaled corticosteroids (asthma) or long-acting bronchodilators (COPD). 
Study variables

RESULTS
Baseline sociodemographic and clinical characteristics
A total of 824 patients were recruited and 816 met all inclusion criteria. The mean patient age was 60 years (range, 18-94) and 445 (54.5%) were men. On average, the patients used 1.8 different inhaler devices, with most patients (n=689) using either only one (266; 32.6%) or two (423; 51.8%) devices; the remaining 127 patients used ≥ 3 (15.6%). Table 1 shows the demographic and clinical characteristics of the study sample.
Adherence
Overall (Table 2, Figure) , 28.6% of patients were non-adherent according to the pharmacy data versus 58.1% according to the TAI (TAI < 50 points). According to the PRR, 37.9% of asthma patients were non-adherent vs. 19.3% of patients with COPD (p<0.001). When both instruments were used in combination, the percentage of nonadherers increased to 64.6%, indicating that the combined data identified more nonadherent patients than either instrument alone. Adherence (mean TAI score) was lower in the asthma group vs. COPD (45.1 vs. 47.0; p<0.001), with 51.5% of patients © 2019 Esmon Publicidad doi: 10.18176/jiaci.0461 with COPD presenting good adherence (TAI=50) versus 32.3% in the asthma groups (p<0.001). Table 3 shows the cross-classification of the patients in terms of adherence or nonadherence as assessed by each method (TAI and PRR). Overall, 35.4% of patients were considered adherent (PRR ≥ 80% and TAI=50) on both measures while 22.1% were non-adherent. Thus, the two tools agreed in 57.5% and disagreed in 42.5% of cases (Table 3 ). Overall agreement between the two measures was weak (k=0.205) ( Table 3 ). (Table 1) reported having received previous training in inhaler use (75.5%) and previous verification of inhalation technique (73.8%). Items 11 and 12 on the TAI are designed to evaluate unwitting non-adherence; as Table 4 shows, patients who previously received training in inhaler use and whose inhaler technique was verified by a professional had significantly higher scores on items 11 and 12.
Concordance between the TAI and PRR
Most of the patients
DISCUSSION
The GINA and other recent guidelines [16] [17] recommend the concomitant use of validated self-report questionnaires and pharmacy refill data to identify non-adherent patients. However, this approach has not been clinically evaluated until now. We found, as expected, that the combined use of these two methods identified a higher percentage of non-adherent patients (64.6%) than either the TAI (58.1%) or pharmacy refill data (28.6%) administered separately. These findings support the value of using this multimeasure approach to reliably identify non-adherent patients. © 2019 Esmon Publicidad doi: 10.18176/jiaci.0461
In clinical settings, self-report instruments are the most commonly-used measures of adherence due to their low-cost, acceptable reliability, and rapid administration time (< 10 minutes for the TAI) [25] . An important advantage of the TAI over more general measures of adherence is its capacity to differentiate between the type of nonadherence-erratic, deliberate, or unwitting, which provides the clinician with valuable information to tailor and implement measures to improve adherence [14, 26] . Another key advantage of the TAI is that it was specifically designed and validated to assess adherence to inhalers.
Pharmacy refill data provide an objective but indirect assessment of adherence-the prescription refill rate. However, the main drawback of this approach to determining adherence is that it can only confirm that the patient has filled the prescription, not whether he/she has taken the medication as prescribed. Despite these disadvantages, pharmacy refill records are non-invasive, widely-available, and can be quickly checked by the physician.
Differences in non-adherence rates between the TAI and pharmacy refill data
In terms of each instrument's relative capacity to identify non-adherence, we found that the TAI identified a significantly higher percentage of non-adherent patients than the refill data (58.1% vs. 28.6%; Table 2 ). This important difference in non-adherence rates identified by the two measures was unexpected. This large disparity is likely due to multiple different factors.. First, studies have shown that patients who report nonadherence on self-reports or clinical interview are likely to be telling the truth [13, 32] .
This would partially explain the discrepancy between the non-adherence rates in our © 2019 Esmon Publicidad doi: 10.18176/jiaci.0461 study, as it is conceivable that some patients picked up their prescriptions-which would explain the "good" adherence identified by the refill data-but then failed to take the medication, subsequently admitting to this failure when completing the TAI.
Second, it seems highly probable that the low non-adherence rates detected by the refill data in our study are related to the low cost of inhalers in Spain (which has universal health care coverage). Third, the 26 participating centers in this study were based in different regions of Spain, each of which uses a different electronic database for pharmacy prescriptions, and difference among these systems may have affected the results. Finally-and perhaps most importantly-the TAI, which is the only validated self-report instrument that specifically assesses adherence to inhalers, may be more accurate than other widely used measures, such as the Morisky-Green test, which assess adherence to "medications" in general rather than inhalers specifically. In short, the TAI may provide a more accurate measure of non-adherence than other selfreport measures, as suggested by the results of the TAI validation study [14] , which demonstrated that the psychometric properties of this instrument are significantly better than those of the Morisky-Green test. Moreover, the fact that only 6.5% of patients considered adherent according to the TAI were non-adherent according to pharmacy records further supports the value of the TAI for determining nonadherence.
With regard to concordance, a review conducted by Lehmann et al. [3] concluded that prescription refill data and self-report measures are only weakly correlated, a finding that is consistent with our results (kappa=0.205). However, de Llano et al. [18] , wholike us-also used the TAI and pharmacy refill data to assess adherence to inhalers (but © 2019 Esmon Publicidad doi: 10.18176/jiaci.0461 
